(Total Views: 526)
Posted On: 07/08/2022 8:41:31 PM
Post# of 148899
Hey MarcS…
I am going to vote yes without a doubt but the company does monitor investor sentiment and saying we should be informed on a direction should be a automatic response by the company. If we complain about not authorizing shares without a plan then maybe they release something we all will value as a direction the management is going to progress our company. We know one thing… if we don’t authorize more shares we will be treading water until the next shareholders meeting and it wouldn’t look good.
I understand that the new president wants cash to make choices on what we are capable of. The communication at just quarterly updates is somewhat of a shock to most of us longs and we are still getting use to that. Most of us still complain a little about the lack of communication but some see it at a good thing that doesn’t allow shorts to run rampant. I like that shorts don’t get big movement and hopefully move on to another stock. A little information on occasion isn’t a bad thing and SEC filings are just that. A little information… I don’t know if I agree with just quarterly updates when the updates seem restricted when we have Q&A time. Like the tough questions are tossed away. That’s my feeling anyway. I will vote yes on both proposals.
Most biotechs bring a drug to market in 12 years and average 2 billion shares before approval. We are below that average and have room for dilution. Nobody likes dilution but it is a necessary financial issue we all have to authorize. We are 10 years and 1 billion shares and moving in both directions to an approval.
If Dr Kelly and our new president and upper management can model us after Humira in a platform drug with a dozen approvals and no partnerships and we keep all the revenue and don’t have to share it with big Pharma. Then they will be hero’s in my eyes. It’s not likely we go it all alone but I would settle for just one more partnership in Nash or mTNBC. Then all the other indications we ride it alone for maximum shareholder value. That’s dream to ride this stock from the bottom to a top 10 pharmaceutical company. It’s like a winning lottery ticket if that happens.
I am going to vote yes without a doubt but the company does monitor investor sentiment and saying we should be informed on a direction should be a automatic response by the company. If we complain about not authorizing shares without a plan then maybe they release something we all will value as a direction the management is going to progress our company. We know one thing… if we don’t authorize more shares we will be treading water until the next shareholders meeting and it wouldn’t look good.
I understand that the new president wants cash to make choices on what we are capable of. The communication at just quarterly updates is somewhat of a shock to most of us longs and we are still getting use to that. Most of us still complain a little about the lack of communication but some see it at a good thing that doesn’t allow shorts to run rampant. I like that shorts don’t get big movement and hopefully move on to another stock. A little information on occasion isn’t a bad thing and SEC filings are just that. A little information… I don’t know if I agree with just quarterly updates when the updates seem restricted when we have Q&A time. Like the tough questions are tossed away. That’s my feeling anyway. I will vote yes on both proposals.
Most biotechs bring a drug to market in 12 years and average 2 billion shares before approval. We are below that average and have room for dilution. Nobody likes dilution but it is a necessary financial issue we all have to authorize. We are 10 years and 1 billion shares and moving in both directions to an approval.
If Dr Kelly and our new president and upper management can model us after Humira in a platform drug with a dozen approvals and no partnerships and we keep all the revenue and don’t have to share it with big Pharma. Then they will be hero’s in my eyes. It’s not likely we go it all alone but I would settle for just one more partnership in Nash or mTNBC. Then all the other indications we ride it alone for maximum shareholder value. That’s dream to ride this stock from the bottom to a top 10 pharmaceutical company. It’s like a winning lottery ticket if that happens.
(4)
(0)Scroll down for more posts ▼
